at development XX% earnings growth. new for million, was markets growth. evening revenue our who XX% you fiscal XXXX. our and EBITDA well Adams, business XX.X you, XX% and on the with Thank Good second was representing will financial glance Kevin. as for our per financial XXXX on Adjusted million, as latest update for our our joining provide provide activities; $X.XX, quick update first-quarter and earnings today Dr. officer, thank representing outlook Adjusted chief representing was numbers Mr. for Orsula will growth. and share and the chief who marketing, officer, XX.X A quarter, us are second-quarter an me Also call. business Brian Knowlton, co-founder
our across aspects performance We had all of business. strong
will Orsula summarize which pipeline, strong a had shortly. for also We you
value mitigating is unique using identifying interactions. by proposition main our software and Our simultaneous multi-drug
deeply chronopharmacology, into the zero of risk grounded Our each and score MedWise science we pharmacogenomics, compile is for XX pharmacodynamics pharmacokinetics, software patient. to in a singular from medication which
In personalization, depicts run thousands a on medication overnight the risk and from histogram millions to of this a cohort patients addition produce we on the number patients the X-axis can Y-axis. the to that scores of and
XXX million exceeds lake data Our patients.
Over our Therapy extensively have data grown past degree They our to Management analytics Medication than personnel. mining Pace have year, we sets. CMS-sponsored internal with Enhanced department data worked more dozen a analytics and sets our the data advanced
to analytics access spending Medication our meds with Management With on We sets information, share Enhanced as the results both reported would XXXX have well data we including prescription, you such information to pilot. these as as drugs, CMS from like visits, physician medical regarding gleaned visits. recreational we I some ER complete time hospitalizations, pharmacotherapy have and of this Therapy last year. over-the-counter,
XXXX We results are received the have now embargoed. which
to scale. medication of stratified had risk with the above XX,XXX is quite In who consult be the XX gleaned from which was with embargoed sorry, XX,XXX CMS -- each signed our our monthly aligned However, also actuaries. tracks X and year risk The identified I progress the approximately department reporting analytics patients group to we which conduct our We on from patients the we XXXX, patients. cohort that the D approximately XXX,XXX a XX able I'm results purview by to Part score will were departments, XX,XXX. were analytics
The to XX and prepare patient a again, days. is telephonic the review and minutes we quarterback prescriber. telephone second is minutes, subsequently retrospective. able to reports telephonic within a limited we XXXX and their it consult preliminary contact risk we In consult telephonic safety along to were XX-minute contact contact, time, with XX,XXX XX-minute send the with medication Prior to patient. one selected to A means medication XX follow-up to review, XX
In contrasts it where Pace other prior contact being is already prospective medication filled is a and the every words, with to taking our medications. ongoing are touch This they with month.
that the MedWise after CMS' So, first X%, our year MedWise even certified of platform with years. spend than which finances by was light reduced medical touch, target and more five
once medical Our also than spend that our analytics determined in interventions reduced X%. by XXXX, department more one-touch again
duplicated risk for only then intervene. consulted whom in we from not a This from almost These switch were medication XXX,XXX risk the was had risk intervention for or at did event XX attracted is an not we patients compared of drug adverse To at XXXX. patients XX. they our XXXX That below patients cohort, bit, we who and scores looked score medication with those gears higher. were the less to
shocking, pharmacies, patients certified MedWise been So the and questions of ask these We was have even found what we by not data. yet interesting, lower our medication touched concerning. most the three risk, at
First, drug MedWise drug between is a rate and hospitalization The with adverse events in correlate medical risk surprising lower adverse And hospitalizations score expenditures? is risk relationship this medication a and how? there Second, and there between events relationship cohort? if results. third, so, does
answer events The in risk First, medication and yes. there a between cohort? reported is the relationship hospitalizatiions the is, drug adverse lower
annual adverse overall events greater reported times X.X times One and per spend correlates greater the medical rate X.X month. of admission them drug with where
events adverse yes. score lower the risk Second, is is, Again, the relationship answer this medication and cohort? between expenditures medical in drug
To third For adverse this would Members XXX,XXX XX-month the we analyst, with MedWise if additional an rate hospitalization entire if answer with risk drug almost that with drug cohort how? the so cost compared so adverse started medical total had correlate event average without and of $XX,XXX question, the is increase reported the event. in patients. members reported
yes. a data. the score. hospital average here's between score And D answer, Part risk XX-month includes XX. and MedWise A, The rate resounding, the correlation is admission strong a There risk harvested MedWise
of XX%. risk score hospital the XX%. and the the admit XX the XX%. unit B, MedWise XX, for XX annual single the $XXX admit is reduction to what of from with medical annual the MedWise each to is score, hospital data C, corresponds to the risk tell rate rate MedWise XX, XX reduction. spend equals point admit The to XX rate or to Furthermore, the drop score us, each equals annual is risk that annual example
and of The number take-home life. data one, is from and legion drug of of this, are all bit this caused quality of degradation a events quite adverse mortality
the data not also We this to indicate, drug that preventative events expect were sufficient but mortality. also, cause of cohort in adverse was a
serious adverse MedWise and from risk be our and life new which predicts regarding interact, deep number how unique score patient. events, drug And medical medications using three, adverse two, simultaneous for caused science hazard those technology, of derived are especially interactions by can most events, quality the Number prevented. work drug a multi-drug
Preventable healthcare adverse also unnecessary drug events result system. expense for in the material
update. news, now for to over her uplifting I'll that it Orsula turn with So
